Pharmaceuticals, Biotechnology and Life Sciences
On Thursday, STADA Arzneimittel AG confirmed that it has received another legally non-binding conditional expression of interest regarding a bid for the acquisition of up to 100 percent of the shares in the company at an indicative takeover price of €58.00 per share.
Alexion Pharmaceuticals’s revenues for 2016 increased 18% compared to the previous year, bringing $3.1 billion, and that’s with a negative impact of foreign currency of 3% or $74 million, bringing net income of $399 million, way up from $144 million last year.
Boston-based pharmaceutical company Rhythm has secured $41 million through mezzanine financing round to funds its melanocortin-4 receptor for the phase 3 study.
Premier Veterinary Group’s subsidiary, Premier Vet Alliance (“PVA”), has signed the third co-operation agreement since its entry to the US market in May 2016.
The U.S. Food and Drug Administration (FDA) has approved Valeant Pharmaceuticals’s Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis.
Swedish Orphan Biovitrum (Sobi) has elected to add a novel product candidate (rFIXFc-XTEN) for the potential treatment of haemophilia B to the company’s collaboration agreement with Bioverativ.
e-Therapeutics’s Executive Director & Company Secretary Sean Nicolson is leaving the company in order to focus on other business commitments.
Denovo Biopharma’s new clinical center in China opened last year will play a very important role in the biomarker driven DB102 trial, as the company has submitted the IND application to the China FDA.
Active Biotech has reported net loss of € 1,6 million for Q4, which is decrease of loss comparing to the same period 2015 when the net loss was € 4,3 million.
Weifa ASA, Norwegian health company has reported net income of € 0,9 million for Q4 2016 which is increase comparing to the same period last year when the comapany had € 0,3 million loss. The company has more than tripled its net income for year 2016. It has reported € 2,03 million for whole 2016 and net income for the 2015 was € 0,65 million.